San Francisco, CA, United States of America

James T Koerber

USPTO Granted Patents = 18 

 

 

Average Co-Inventor Count = 6.3

ph-index = 8

Forward Citations = 329(Granted Patents)


Location History:

  • Oakland, CA (US) (2014)
  • San Francisco, CA (US) (2015 - 2024)
  • San Mateo, CA (US) (2024)

Company Filing History:


Years Active: 2014-2025

Loading Chart...
Loading Chart...
Loading Chart...
18 patents (USPTO):Explore Patents

Title: **James T. Koerber: Innovator in Antibody Therapies**

Introduction

James T. Koerber is a prominent inventor based in San Francisco, CA, known for his significant contributions to the field of antibody therapies. With an impressive portfolio of 18 patents, he has developed innovative solutions that address critical health challenges through his work on antibody-based treatments.

Latest Patents

Koerber's latest patents showcase his expertise in the development of monoclonal antibodies. These include:

- Anti-KLK7 antibodies, anti-KLK5 antibodies, and multispecific anti-KLK5/KLK7 antibodies, offering methods of use for effective therapeutic applications.

- Anti-C-C motif chemokine receptor 8 (CCR8) antibodies, along with their preparation and use, further enhancing his contributions to targeted cancer therapies.

Career Highlights

Throughout his career, James T. Koerber has held esteemed positions at leading institutions such as the University of California and Genentech, Inc. His work has continued to push the boundaries of biomedical research, resulting in groundbreaking innovations that are paving the way for future therapeutic strategies.

Collaborations

Koerber has collaborated with notable individuals in the field, including David V. Schaffer and Ryan R. Klimczak. These partnerships have fostered an environment of innovation and scientific advancement, enabling the development of new therapies and applications based on antibody technology.

Conclusion

With a robust portfolio of patents and a solid background in prestigious research institutions, James T. Koerber stands out as a key contributor to the advancements in antibody therapies. His continued commitment to innovation not only benefits the scientific community but also offers hope for improved treatments in the healthcare sector.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…